Clinical Trial Update: Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing efficacy and safety of everolimus in de novo heart transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Transplantation | Phase 3 | Status: COMPLETED